We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Reata Pharmaceuticals Inc
7 own
8 watching
Current Price
$0
$-0.28
(-0.57%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,812.62M
52-Week High
50.99
52-Week Low
18.47
Average Volume
0.5M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,812.62M52-Week High50.9952-Week Low18.47Average Volume0.5MDividend Yield--P/E Ratio--What does the Reata Pharmaceuticals Inc do?
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company focuses on drugs with novel mechanisms of action that modulate regulatory proteins called transcription factors. Its lead product candidates include bardoxolone methyl and RTA 408, which are members of a class of small molecules called antioxidant inflammation modulators. It is involved in LARIAT, a Phase II study of bardoxolone methyl for the treatment of pulmonary arterial hypertension and pulmonary hypertension due to interstitial lung disease. RTA 408 is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia and mitochondrial myopathies. Reata Pharmaceuticals, Inc. was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.
Read More
How much money does Reata Pharmaceuticals Inc make?
News & Events about Reata Pharmaceuticals Inc.
Globe Newswire
4 months ago
NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) breached their fiduciary duties to shareholders. The investigation concerns potential ...
PR Newswire
4 months ago
Thinking about buying stock in Neximmune, ShiftPixy, IN8BIO, Relay Therapeutics, or Reata Pharmaceuticals? Thinking about buying stock in Neximmune, ShiftPixy, IN8BIO, Relay Therapeutics, or Reata Pharmaceuticals? PR Newswire NEW YORK, Sept. 8, 2022 NEW YORK, Sept. 8, 2022 /PRNewswire...
Zolmax
8 months ago
Reata Pharmaceuticals (NASDAQ:RETA Get Rating) had its price objective lifted by Citigroup from $43.00 to $46.00 in a report issued on Friday morning, The Fly reports. The firm currently has a buy rating on the stock. A number of other equities analysts have also weighed in on the company. StockNews...
Frequently Asked Questions
Frequently Asked Questions
What is Reata Pharmaceuticals Inc share price today?
Can Indians buy Reata Pharmaceuticals Inc shares?
How can I buy Reata Pharmaceuticals Inc shares from India?
Can Fractional shares of Reata Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Reata Pharmaceuticals Inc stocks?
What is today’s traded volume of Reata Pharmaceuticals Inc?
What is today’s market capitalisation of Reata Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Reata Pharmaceuticals Inc?
What percentage is Reata Pharmaceuticals Inc down from its 52-Week High?
What percentage is Reata Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$0
$-0.28
(-0.57%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.